Multiple myeloma (MM) is a genetically heterogeneous disease that includes a subgroup of
10–15% of patients facing dismal survival despite the most intensive treatment. Despite …

Recent research has dramatically advanced our understanding of the genetic basis of
multiple myeloma (MM). MM displays enormous inter-and intratumoral heterogeneity, and …

Multiple myeloma (MM), one of the most intractable malignancies, is characterized by the
infiltration and growth of plasma cells, the most differentiated cells in the B-cell lineage, in …

Multiple myeloma (MM) is a unique cancer paradigm for investigating the mechanisms
involved in the transition from a premalignant condition (monoclonal gammopathy of …

Multiple myeloma (MM) is characterised by the expansion of monoclonal immunoglobulin-
secreting plasma cells. Despite recent advances in systemic and supportive therapy, it …

Clonal heterogeneity and clonal evolution have emerged as critical concepts in the field of
oncology over the past four decades, largely thanks to the implementation of novel …

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant
expansion of plasma cells within the bone marrow, as well as at extramedullary sites …

Multiple myeloma (MM) is an incurable malignancy in majority of patients characterized by
clonal proliferation of plasma cells. To date, treatment is established based on general …

The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …